Aduro Biotech (ADRO) Posts Q1 Loss of $39.97/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aduro Biotech Announces First Quarter 2015 Financial Results
May 28, 2015 4:00 PM EDTEstablished major $750M collaboration with Novartis for STING in oncology Strengthened cash position with $200M upfront payment from Novartis and $149.3M in net proceeds from IPO and concurrent private placement in April 2015 Achieved prostate cancer milestone with Janssen's LADD strain selection Initiated STELLAR Phase 2 trial in pancreatic cancer with LADD + checkpoint inhibitor Received Orphan Drug Designation for mesothelioma immunotherapy
BERKELEY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO),... More
Aduro Biotech Announces First Quarter 2015 Financial Results
May 28, 2015 4:00 PM EDTEstablished major $750M collaboration with Novartis for STING in oncology Strengthened cash position with $200M upfront payment from Novartis and $149.3M in net proceeds from IPO and concurrent private placement in April 2015 Achieved prostate cancer milestone with Janssen's LADD strain selection Initiated STELLAR Phase 2 trial in pancreatic cancer with LADD + checkpoint inhibitor Received Orphan Drug Designation for mesothelioma immunotherapy
BERKELEY, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO),... More
